Clinical Trial: A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients

U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07177859) titled 'A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients' on Sept. 10.

Brief Summary: NTQ5082 capsules are a small molecule CFB inhibitor. This study is a multicenter, randomized, open-label, active-controlled Phase III clinical trial designed to evaluate the efficacy and safety of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Paroxysmal Nocturnal Hemoglobinuria

Intervention: DRUG: NTQ5082 capsules 200 mg

NTQ5082 capsules 200 mg

DRUG: Eculizumab Injection

Eculizumab

Rec...